Review Article
Towards Personalized Medicine Based on Platelet Function Testing for Stent Thrombosis Patients
Table 4
Overview on how to decide to optimize personalized medicine for P2Y12 inhibitors per patient.
| |
Number of platelet function tests for P2Y12 inhibitor that shows | | | | NPR | HPR | How is the patient treated with current APT? | What to do with the APT? |
| | 3 | 0 | Well treated | Current APT can be continued | 2 | 1 | Well treated | Current APT can be continued | 1 | 2 | Undertreated | Switch APT; consider (i) Clinical characteristics (ii) Comedication (iii) Genetics | 0 | 3 | Undertreated | Switch APT; consider: (i) Clinical characteristics (ii) Comedication (iii) Genetics |
|
|
NPR: normal on-treatment platelet reactivity; HPR: high on-treatment reactivity; APT: antiplatelet therapy.
|